Physician profile
Michael G Posner
NPI 1447247093
$2,252.43
in general payments reported to CMS, 2019-2025
19 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $157 · 2021: $267 · 2022: $487 · 2023: $402 · 2024: $215 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $706.52 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Stellaris |
| Sun Pharmaceutical Industries INC. | $224.39 | 2019-2024 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $179.58 | 2020-2025 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $163.37 | 2019-2023 | |
| Alcon Vision LLC | $151.89 | 2019-2025 | Hydrus Microstent, Tryptyr, Simbrinza |
| Allergan, INC. | $147.04 | 2019-2021 | |
| Glaukos Corporation | $139.68 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.65 | 2019 | |
| Astellas Pharma US INC | $97.03 | 2025 | Izervay |
| Genentech USA, INC. | $65.07 | 2025 | Vabysmo |
| Kala Pharmaceuticals, INC. | $64.20 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $37.34 | 2025 | Xdemvy |
| Amgen INC. | $34.27 | 2025 | Tepezza |
| Dompe US, INC. | $33.41 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $24.11 | 2023 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $15.19 | 2025 | Syfovre |
| Sight Sciences, INC. | $13.75 | 2023 | Omni Surgical System |
| Johnson & Johnson Vision Care, INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.